Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience

Enzalutamide and abiraterone have been shown to improve progression-free survival (PFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients. Moreover, some patients may not benefit from the inhibition of androgen receptor (AR) activity or, alternatively, may...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Sepe, Pierangela, Verzoni, Elena, Miodini, Patrizia, Claps, Melanie, Ratta, Raffaele, Martinetti, Antonia, Mennitto, Roberta, Sottotetti, Elisa, Procopio, Giuseppe, Cappelletti, Vera, Daidone, Maria Grazia
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6678845/
https://ncbi.nlm.nih.gov/pubmed/31337040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11070980
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars